Last reviewed · How we verify

FlexHD

University of Arkansas · FDA-approved active Biologic

FlexHD is a flexible hemodynamic support device designed to provide temporary mechanical circulatory support.

FlexHD is a flexible hemodynamic support device designed to provide temporary mechanical circulatory support. Used for Cardiogenic shock requiring temporary mechanical circulatory support, Acute decompensated heart failure.

At a glance

Generic nameFlexHD
SponsorUniversity of Arkansas
ModalityBiologic
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

FlexHD functions as a percutaneous ventricular assist device that can be rapidly deployed to support failing hearts during acute decompensation or cardiogenic shock. The device provides hemodynamic stabilization by mechanically unloading the left ventricle and improving systemic perfusion, allowing time for myocardial recovery or bridge to definitive therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: